For many years, the Cancer Drug Development Forum (CDDF) has focused on developing initiatives that accelerate effective drug development in oncology treatment, reduce time to market, and improve patient access.
The CDDF offers workshops, conferences and webinars that bring stakeholders involved in cancer drug development into a productive dialogue in a neutral, non-competitive space. The CDDF holds multiple activities and initiatives in collaboration with regulators from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). These, and other regulatory agencies, join academic researchers from around the globe, pharmaceutical companies, and patient advocates to advance cancer drug development.
The Cancer Drug Development Forum (CDDF) Spring Conference is a unique annual meeting. This multi-stakeholder, interactive 3-day meeting offers plenary lectures with moderated discussions, including case studies and networking opportunities. In addition to the Spring conference, the CDDF organises workshops to facilitate multi-stakeholder collaboration on topical issues in the cancer research field.
The responsive nature of the CDDF platform means that programs can be quickly initiated or adapted to reflect current and pressing issues. Since its inception, CDDF has proved to be a visionary force within the cancer drug development field addressing topics such as: immuno-oncology, the use of real-world data in cancer drug development and improving outcomes for children and adolescents with cancer through the ACCELERATE platform launched in 2013.
The CDDF continues to pioneer progress in cancer drug treatments through upcoming workshops, which explore the potential impact of digital health and artificial intelligence on cancer patients.
The CDDF publishes reports prepared from workshops discussions, conference presentations and lecture briefings to increase awareness of the challenges and opportunities in cancer drug development.